Ex vivo study evaluates bioactivity of modified glass-ionomers for pulp-capping, suggesting a new alternative.
offers a potential preclinical alternative for pulp-capping, though its bioactivity requires further optimization.
No takes yet. Share an insight, caveat, or question.
Somudorn et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: